Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.
This article dedicated to an update review of molecular targets could potentially be used for target therapy of lung cancer using SiRNA technology. PMID: 29336624 [PubMed - as supplied by publisher]
CONCLUSION: Immune checkpoint inhibitors are a potential treatment for solid organ transplant patients despite the risk of graft rejection. PMID: 31611026 [PubMed - as supplied by publisher]
ConclusionPLN metastasis was a quite common pattern of LN metastasis in N1 station of NSCLC. IPLNM occurred more frequently in central NSCLC and NSCLC with vascular invasion, and thoracotomy was likely to secure more accurate PLN staging. Clinicians should pay great attention to PLN dissection. Follow ‐up data will be needed in order to detect the prognosis of IPLNM patients.
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, with 2.1 million new lung cancer cases and 1.8 million deaths per year [1 –4]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Up to 61% of patients have advanced disease at the time of diagnosis, with a 5-year survival rate of 18% [5,6].
ABSTRACT Objective: Preoperative functional evaluation is central to optimizing the identification of patients with non-small cell lung cancer (NSCLC) who are candidates for surgery. The minute ventilation/carbon dioxide output (VE/VCO2) slope has proven to be a predictor of surgical complications and mortality. Pulmonary rehabilitation programs (PRPs) could influence short-term outcomes in patients with COPD undergoing lung resection. Our objective was to evaluate the effects of a PRP on the VE/VCO2 slope in a cohort of patients with COPD undergoing lung resection for NSCLC. Methods: We retrospectively evaluated 25 consec...
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
In non-small cell lung cancer (NSCLC) patients, concomitant idiopathic pulmonary fibrosis (IPF) and emphysema (CPFE) are independently related to poor survival. CPFE is a condition with features of both pulmon...
Conclusion: This study identified a local “driver-network” and its upstream regulators responsible for the cell proliferation in NSCLC, which could be promising biomarkers and therapeutic targets for NSCLC treatment.
We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, including off-label combination of crizotinib +...
In conclusion, tumor imaging phenotypes that are driven by somatic mutations may be predicted by radiomics based on PET/CT images.